MedPath

Galderma Group AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
$22.9B
Website
http://www.galderma.com/

Treatment of Moderate to Severe Glabellar Lines

Phase 3
Completed
Conditions
Glabellar Frown Lines
First Posted Date
2020-01-31
Last Posted Date
2023-06-18
Lead Sponsor
Galderma R&D
Target Recruit Count
300
Registration Number
NCT04249583
Locations
🇺🇸

\Ablon Skin Institute and Research Center, Manhattan Beach, California, United States

🇺🇸

Moradi MD, Vista, California, United States

🇺🇸

Etre Cosmetic Dermatology and Laser Center, New Orleans, Louisiana, United States

and more 11 locations

Treatment of Moderate to Severe Lateral Canthal Lines

Phase 3
Completed
Conditions
Lateral Canthal Lines
First Posted Date
2020-01-31
Last Posted Date
2023-06-18
Lead Sponsor
Galderma R&D
Target Recruit Count
303
Registration Number
NCT04249687
Locations
🇺🇸

Ablon Skin Institute and Research Center, Manhattan Beach, California, United States

🇺🇸

Dermatology Cosmetic Laser Medical Associates, San Diego, California, United States

🇺🇸

Art of Skin, MD, Solana Beach, California, United States

and more 7 locations

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

Phase 3
Completed
Conditions
Glabellar Frown Lines (GL)
Lateral Canthal Lines (LCL)
First Posted Date
2020-01-29
Last Posted Date
2023-09-06
Lead Sponsor
Galderma R&D
Target Recruit Count
413
Registration Number
NCT04247074
Locations
🇺🇸

Clinical Testing of Beverly Hills, Encino, California, United States

🇺🇸

Ava MD, Santa Monica, California, United States

🇺🇸

Skin Care & Laser Physicians of Beverly Hills, West Hollywood, California, United States

and more 9 locations

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

Phase 3
Completed
Conditions
Glabellar Lines
Lateral Canthal Lines
First Posted Date
2020-01-13
Last Posted Date
2023-06-18
Lead Sponsor
Galderma R&D
Target Recruit Count
902
Registration Number
NCT04225260
Locations
🇺🇸

Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States

🇺🇸

Investigate MD, LLC., Scottsdale, Arizona, United States

🇺🇸

Center for Dermatology Clinical Research, Inc., Fremont, California, United States

and more 27 locations

Extension Study for 43USSA1705

Not Applicable
Completed
Conditions
Nasolabial Folds
First Posted Date
2020-01-13
Last Posted Date
2025-03-12
Lead Sponsor
Galderma R&D
Target Recruit Count
38
Registration Number
NCT04225273
Locations
🇺🇸

Galderma Study Site, Spring, Texas, United States

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Phase 3
Active, not recruiting
Conditions
Prurigo Nodularis
Interventions
First Posted Date
2019-12-19
Last Posted Date
2024-11-05
Lead Sponsor
Galderma R&D
Target Recruit Count
500
Registration Number
NCT04204616
Locations
🇬🇧

Galderma Investigational Site, Newcastle Upon Tyne, United Kingdom

🇺🇸

Galderma Investigational Galderma Investigational Site, Springville, Utah, United States

🇺🇸

Galderma I Galderma Investigational Site, Lake Bluff, Illinois, United States

and more 1 locations

Restylane-L for Correction of Infraorbital Hollows

Not Applicable
Completed
Conditions
Infraorbital Hollows
First Posted Date
2019-11-07
Last Posted Date
2023-04-25
Lead Sponsor
Galderma R&D
Target Recruit Count
333
Registration Number
NCT04154930
Locations
🇺🇸

Galderma Research Site, Spring, Texas, United States

Sculptra for Correction of Midface Volume Deficit and/or Midface Contour Deficiency

Not Applicable
Completed
Conditions
Midface Volume Deficit
First Posted Date
2019-10-18
Last Posted Date
2025-01-07
Lead Sponsor
Galderma R&D
Target Recruit Count
205
Registration Number
NCT04132518
Locations
🇨🇳

Galderma research site 3, Beijing, China

🇨🇳

Galderma research site 4, Beijing, China

🇨🇳

Galderma research site 5, Chengdu, China

and more 3 locations

Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles

Not Applicable
Completed
Conditions
Cheek Wrinkles
First Posted Date
2019-10-11
Last Posted Date
2023-11-18
Lead Sponsor
Galderma R&D
Target Recruit Count
149
Registration Number
NCT04124692
Locations
🇺🇸

Galderma Research Site, Spring, Texas, United States

Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face

Phase 3
Completed
Conditions
Actinic Keratoses
Interventions
Drug: MAL 16.8% cream
Drug: MAL Vehicle Cream
First Posted Date
2019-09-11
Last Posted Date
2022-04-01
Lead Sponsor
Galderma R&D
Target Recruit Count
557
Registration Number
NCT04085367
Locations
🇺🇸

Galderma Investigational Site (Site 8768), Tucson, Arizona, United States

🇺🇸

Galderma Investigational Site (Site 8447), Fort Smith, Arkansas, United States

🇺🇸

Galderma Investigational Site (Site 8577), Encinitas, California, United States

and more 57 locations
© Copyright 2025. All Rights Reserved by MedPath